Apogee Technology Receives Notice from American Stock Exchange

  
    
  
  
    
      Apogee Technology, Inc. (AMEX: ATA), was notified on November 1, 2006 
      that it does not meet certain continued listing standards, as set forth 
      in Part 10 of the AMEX Company Guide (the “Company 
      Guide”) and has therefore become subject to 
      the procedures and requirements of Section 1009 of the Company Guide. As 
      the Company shareholders’ equity was 
      approximately $3.97 million as of June 30, 2006, the Company is not in 
      compliance with Section 1003 (a) (ii) of the Company Guide as it has 
      shareholders’ equity of less than $4 million 
      and losses from continuing operations and/or net losses in three out of 
      its four most recent fiscal years. The Company is also not in compliance 
      with Section 1003 (a) (iii) of the Company Guide as it has shareholders’ 
      equity of less than $6 million and losses from continuing operations in 
      its five most recent fiscal years.
    
    
      According to the AMEX notice, the Company must submit a plan by December 
      1, 2006, advising of the action it has taken, or will take, to bring the 
      Company into compliance with Sections 1003(a) (ii) and 1003(a) (iii) of 
      the Company Guide within a maximum of 12 months.
    
    
      If the plan is accepted, the Company will be permitted to continue its 
      listing during the plan period, but such continued listing will be 
      subject to periodic review to determine whether the Company is making 
      progress consistent with the plan. The Company intends to issue a formal 
      plan to AMEX before December 1, 2006.
    
    
      About Apogee Technology, Inc.
    
    
      Apogee Technology designs, develops and commercializes proprietary 
      medical device and sensor products using its micro-systems and 
      nanotechnology for the medical, automotive, industrial and consumer 
      markets. The Company is developing its PyraDerm™ 
      solution for enhanced intradermal drug delivery and has introduced a 
      family of pressure sensors under the Sensilica™ 
      brand. Apogee’s goal is to provide value-added 
      and cost-savings solutions for our customers and, in so doing, to become 
      a global leader in the sensor and medical device fields. For more 
      information please visit our web site at: http://www.apogeemems.com.
    
    
      PyraDerm™ and Sensilica™ 
      are trademarks of Apogee Technology, Inc. All other product names noted 
      herein may be trademarks of their respective holders. Certain statements 
      made herein that use the words "anticipate," "hope," "estimate," 
      "project," "intend," "plan," "expect," "believe" and similar expressions 
      are intended to identify forward-looking statements within the meaning 
      of the Private Securities Litigation Reform Act of 1995. These 
      forward-looking statements involve known and unknown risks and 
      uncertainties, which could cause the actual results, performance or 
      achievements of the Company to be materially different from those that 
      may be expressed or implied. Please refer to the company's risk factors 
      as set forth in the Company's filings with the Securities and Exchange 
      Commission, including its reports on Forms 10-KSB and 10-QSB.
    
  
Apogee Technology, Inc. (AMEX: ATA), was notified on November 1,
2006 that it does not meet certain continued listing standards, as set
forth in Part 10 of the AMEX Company Guide (the "Company Guide") and
has therefore become subject to the procedures and requirements of
Section 1009 of the Company Guide. As the Company shareholders' equity
was approximately $3.97 million as of June 30, 2006, the Company is
not in compliance with Section 1003 (a) (ii) of the Company Guide as
it has shareholders' equity of less than $4 million and losses from
continuing operations and/or net losses in three out of its four most
recent fiscal years. The Company is also not in compliance with
Section 1003 (a) (iii) of the Company Guide as it has shareholders'
equity of less than $6 million and losses from continuing operations
in its five most recent fiscal years.

   According to the AMEX notice, the Company must submit a plan by
December 1, 2006, advising of the action it has taken, or will take,
to bring the Company into compliance with Sections 1003(a) (ii) and
1003(a) (iii) of the Company Guide within a maximum of 12 months.

   If the plan is accepted, the Company will be permitted to continue
its listing during the plan period, but such continued listing will be
subject to periodic review to determine whether the Company is making
progress consistent with the plan. The Company intends to issue a
formal plan to AMEX before December 1, 2006.

   About Apogee Technology, Inc.

   Apogee Technology designs, develops and commercializes proprietary
medical device and sensor products using its micro-systems and
nanotechnology for the medical, automotive, industrial and consumer
markets. The Company is developing its PyraDerm(TM) solution for
enhanced intradermal drug delivery and has introduced a family of
pressure sensors under the Sensilica(TM) brand. Apogee's goal is to
provide value-added and cost-savings solutions for our customers and,
in so doing, to become a global leader in the sensor and medical
device fields. For more information please visit our web site at:
http://www.apogeemems.com.

   PyraDerm(TM) and Sensilica(TM) are trademarks of Apogee
Technology, Inc. All other product names noted herein may be
trademarks of their respective holders. Certain statements made herein
that use the words "anticipate," "hope," "estimate," "project,"
"intend," "plan," "expect," "believe" and similar expressions are
intended to identify forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve known and unknown risks and
uncertainties, which could cause the actual results, performance or
achievements of the Company to be materially different from those that
may be expressed or implied. Please refer to the company's risk
factors as set forth in the Company's filings with the Securities and
Exchange Commission, including its reports on Forms 10-KSB and 10-QSB.